Kristen J. Rasmussen

Kristen J. Rasmussen

Auto-generated profile, based on publicly available information

Kristen J. Rasmussen

Mayo Clinic

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2019 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
PNPantelis Nicola
Pantelis Nicola
PBPatrick Blackburn
Patrick Blackburn
KRKristen J. Rasmussen
Kristen J. Rasmussen
NBNicole L. Bertsch
Nicole L. Bertsch
EKEric W. Klee
Eric W. Klee
JCJill Clayton‐Smith
Jill Clayton‐Smith

1 June 2020 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
TDTheodore G. Drivas
Theodore G. Drivas
DLDong Li
Dong Li
DNDivya Nair
Divya Nair
JAJoseph T. Alaimo
Joseph T. Alaimo
MAMariëlle Alders
Mariëlle Alders
EBElizabeth Bhoj
Elizabeth Bhoj

22 September 2022 in medRxiv
Verified
Preprint
Open access
PDF file
HHeidi Rehm
Heidi Rehm
JAJoseph T Alaimo
Joseph T Alaimo
SASwaroop Aradhya
Swaroop Aradhya
PBPinar Bayrak-Toydemir
Pinar Bayrak-Toydemir
HBHunter Best
Hunter Best
MIMedical Genome Initiative
Medical Genome Initiative
PURPOSE: Variants of uncertain significance (VUS) are a common result of diagnostic genetic testing and can be difficult to manage with potential misinterpretation and downstream costs, including time investment by clinicians. We investigated the rate of VUS reported on diagnostic testing via multi-gene panels (MGPs) and exome and genome sequencing (ES/GS) to measure the magnitude of uncertain results and explore ways to reduce their potentially detrimental impact. METHODS: Rates of inconclusive results due to VUS were collected from over 1.5 million sequencing test results from 19 clinical laboratories in North America from 2020 - 2021. RESULTS: We found a lower rate of inconclusive test results due to VUSs from ES/GS (22.5%) compared to MGPs (32.6%; p<0.0001). For MGPs, the rate of inconclusive results correlated with panel size. The use of trios reduced inconclusive rates (18.9% vs 27.6%; p<0.001) whereas the use of GS compared to ES had no impact (22.2% vs 22.6%; p=ns). CONCLUSION: The high rate of VUS observed in diagnostic MGP testing warrants examining current variant reporting practices. We propose several approaches to reduce reported VUS rates, while directing clinician resources towards important VUS follow-up.

21 March 2022 in Genetics in Medicine
Verified
Journal Article
Closed access
HSHeidi Sellers
Heidi Sellers
MSMariam Stein
Mariam Stein
PTPratyush Tandale
Pratyush Tandale
JTJiayu Tan
Jiayu Tan
RSRohit Setlem
Rohit Setlem
WSWei Shen
Wei Shen